ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est

Benzinga Newsdesk www.benzinga.com Negative 56.3%

Neg 56.3% Neu 0% Pos 0%

ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080 billion-$1.140 billion vs $1.119 billion estimate.